[Ala2,8,9,11,19,22,24,25,27,28]-VIP

Discontinued Product

[Ala2,8,9,11,19,22,24,25,27,28]-VIP (Cat. No. 3095) has been withdrawn from sale for commercial reasons.
Cat.No. 3095 - [Ala2,8,9,11,19,22,24,25,27,28]-VIP | His-Ala-Asp-Ala-Val-Phe-Thr-Ala-Ala-Tyr-Ala-Arg-Leu-Arg-Lys-Gln-Met-Ala-Ala-Lys-Lys-Ala-Leu-Ala-Ala-Ile-Ala-Ala-NH2 | CAS No. 866552-34-3
Description: Highly selective VPAC1 agonist
Datasheet
Citations
Reviews
Literature

Biological Activity

Highly selective agonist for the VPAC1 receptor (IC50 values are ~ 11.5-13.2 and > 30000 nM for VPAC1 and VPAC2 receptors respectively).

Technical Data

M. Wt 2928.49
Formula C131H219N41O33S
Sequence HADAVFTAAYARLRKQMAAKKALAAIAA

(Modifications: Ala-28 = C-terminal amide)

Storage Store at -20°C
CAS Number 866552-34-3
Smiles [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(N)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Igarashi et al (2005) Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. J.Pharmacol.Exp.Ther. 315 370 PMID: 15994369

View Related Products by Target

View Related Products by Product Action

View all VIP Receptor Agonists

Keywords: [Ala2,8,9,11,19,22,24,25,27,28]-VIP, [Ala2,8,9,11,19,22,24,25,27,28]-VIP supplier, selective, VPAC1, agonists, Vasoactive, Intestinal, Peptide, Receptors, VIP, 3095, Tocris Bioscience

Citations for [Ala2,8,9,11,19,22,24,25,27,28]-VIP

Citations are publications that use Tocris products.

Currently there are no citations for [Ala2,8,9,11,19,22,24,25,27,28]-VIP.

Reviews for [Ala2,8,9,11,19,22,24,25,27,28]-VIP

There are currently no reviews for this product. Be the first to review [Ala2,8,9,11,19,22,24,25,27,28]-VIP and earn rewards!

Have you used [Ala2,8,9,11,19,22,24,25,27,28]-VIP?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Peptide Hormone Receptors

Peptide Hormone Receptors Product Listing

A collection of over 200 products for peptide hormone receptors, the listing includes research tools for the study of:

  • Anterior Pituitary Regulation
  • Blood Pressure Regulation
  • Feeding and Appetite Regulation
  • Glucose Regulation
  • Peptide Hormone Processing
Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.